KalVista Pharmaceuticals's total assets for Q2 2025 were $160.83M, a decrease of -19.66% from the previous quarter. DE:4XC1 total liabilities were $26.84M for the fiscal quarter, a -2.04% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.